U.S. gov awards CSL Biotherapies contract for influenza pandemic preparedness

Friday, September 14, 2012 12:07 PM

CSL Biotherapies, a King of Prussia, Penn.-based subsidiary of CSL Limited, a manufacturers of influenza vaccines, has been awarded a contract by the U.S. Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

The U.S. government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.

Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services’ office of the assistant secretary for preparedness and response, biomedical advanced R&D authority. The contract has a maximum potential value of $1.5 billion if all optional activities are exercised over the duration of the contract.

"We are very pleased to again be working with the U.S. government on its pandemic preparedness efforts," said Dr. John Anderson, senior vice president of CSL Biotherapies. "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs